Based on these results, the US FDA approved the pembrolizumab as a single-agent first-line immunotherapy in patients with advanced NSCLC harboring high PD-L1 expression (PD-L1 ≥ 50%) and no EGFR/ALK mutations (Pai-Scherf et al., 2017). Here, ALK is linked to non-small cell lung carcinoma.